Clinical Utility of Antipeptidyl Arginine Deiminase Type 4 Antibodies.

Clinical Utility of Antipeptidyl Arginine Deiminase Type 4 Antibodies.
J Rheumatol. 2019 Jan 15;:
Authors: Darrah E, Martinez-Prat L, Mahler M
Abstract
Rheumatoid factor (RF) and anticitrullinated protein antibodies (ACPA) are important biomarkers in the diagnosis of rheumatoid arthritis (RA) but leave a gap of > 50% seronegative in early RA1 In addition, there is marked clinical heterogeneity in the seropositive group, precluding the use of RF and ACPA alone as prognostic biomarkers. These characteristics drive the demand for novel diagnostic and prognostic markers in RA1.
PMID: 30647163 [PubMed - as supplied by publisher]

Source: J Rheumatol - January 15, 2019 Category: Rheumatology Authors: Darrah E, Martinez-Prat L, Mahler M Tags: J Rheumatol Source Type: research